Assessing the magnitude of antiemetic benefit with the addition of the NK1 receptor antagonist (NK1) aprepitant for all platinum agents: Analysis of 1,872 patients (pts) in prospective randomized clinical phase III trials (RCTs).
2010 ◽
Vol 28
(15_suppl)
◽
pp. 9057-9057
◽
Keyword(s):
2016 ◽
Vol 34
(15_suppl)
◽
pp. 10019-10019
◽
Keyword(s):
2002 ◽
Vol 133
(2)
◽
pp. 363-368
◽
Keyword(s):
Keyword(s):
1993 ◽
Vol 249
(1-2)
◽
pp. R3-R4
◽
2012 ◽
Vol 684
(1-3)
◽
pp. 64-70
◽
Keyword(s):
Keyword(s):
Keyword(s):
2003 ◽
Vol 461
(2-3)
◽
pp. 197-206
◽
Keyword(s):